Recent Updates
Recently added Catalysts
HOWL Positive Sentiment

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Monday, January 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Werewolf Therapeutics has provided a business update detailing its strategic outlook for 2024. The company focuses on developing conditionally activated therapeutics aimed at enhancing the immune response in cancer treatment. The update includes expected milestones that reflect the company's commitment to innovation in biopharmaceuticals.
Price reaction · baseline $5.36 (2024-01-05 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close · peak
-4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Werewolf Therapeutics is pioneering innovative therapies.
  • The company is focused on stimulating the immune system for cancer treatment.
  • A clear strategic outlook and expected milestones for 2024 are outlined.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors

Full Press Release Details

WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.

Frequently Asked Questions

What is Werewolf Therapeutics focused on?

Werewolf Therapeutics is focused on developing conditionally activated therapeutics for cancer.

What did Werewolf Therapeutics announce for 2024?

The company announced its strategic outlook and expected milestones for 2024.

ShareAdd on Google
Tags: HOWL Viatris Investor Conferences Healthcare Werewolf Therapeutics cancer treatment biopharmaceuticals immune system
Last updated: Jan 8, 2024

Biotech snapshot

Cash runway
$22M liquidity · $0M/mo burn
Low dilution risk
Lead asset
WTX-330Phase 1
Advanced or Metastatic Solid Tumors →

Catalyst track record

+25%
best trade around HOWL's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for HOWL.

See every catalyst's timing & PoA →